Anavex Life Sciences Corp (AVXL)

[Doc328]

Neuren/Acadia had an SPA for trofinetide in Rett and had agreed upon entry criteria, endpoints, method of analysis, and n -- this led to smooth sailing for the NDA and approval after their successful P3 . AVXL stated in June they will be using the same endpoints/method of analysis that Neuren had worked out with the FDA in their SPA. So if Missling doesn't go off script again, AVXL has a clear path --- assuming significance is reached and assuming the FDA is cool with the lower n. .